Role of miRNAs in CVD and Periodontitis

University of Catania115 enrolled

Overview

Several micro-RNA plays a key role in endothelial function and may be a link for the known interaction of periodontitis and cardiovascular disease. The investigators compared the impact of gingival health, periodontitis (CP), cardiovascular disease or of both diseases (CP +cardiovascular disease) on gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.

The investigators compared the impact of gingival health, periodontitis (CP), cardiovascular disease or of both diseases (CP +cardiovascular disease) on gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.

Study Type

OBSERVATIONAL

Enrollment

115

Conditions

Cardiovascular Diseases Periodontal Diseases

Interventions

Observation of Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.OTHER

Evaluation of gingival crevicular fluid miRNA 7a-5p, miRNA 21-3p, miRNA 21-5p, miRNA 200b-3p, miRNA 200b-5p, miRNA 100-5p, miRNA 125-5p levels.

Eligibility

Medical Language ↔ Plain English

Inclusion Criteria: * Presence of at least 15 teeth * CP with a minimum of 40% of sites with a clinical attachment level (CAL) ≥2mm and probing depth (PD) ≥4mm; * Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs * Presence of ≥40% sites with bleeding on probing (BOP) Exclusion Criteria: * Intake of contraceptives * Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study * Status of pregnancy or lactation * Previous history of excessive drinking * Allergy to local anaesthetic * Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.

Locations (1)

University of Catania

Catania, CT, Italy

Outcomes

Primary Outcomes

Clinical Attachment level

Evaluation of changes (in millimeters) of Clinical attachment level loss

Time frame: 1-year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.